These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27502784)

  • 1. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
    McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
    J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
    Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
    Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
    J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
    Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
    J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
    Lou E; Peters KB; Sumrall AL; Desjardins A; Reardon DA; Lipp ES; Herndon JE; Coan A; Bailey L; Turner S; Friedman HS; Vredenburgh JJ
    Cancer Med; 2013 Apr; 2(2):185-95. PubMed ID: 23634286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
    Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
    Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
    Nabors LB; Fiveash JB; Markert JM; Kekan MS; Gillespie GY; Huang Z; Johnson MJ; Meleth S; Kuo H; Gladson CL; Fathallah-Shaykh HM
    Arch Neurol; 2010 Mar; 67(3):313-9. PubMed ID: 20212229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
    Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab and daily temozolomide for recurrent glioblastoma.
    Desjardins A; Reardon DA; Coan A; Marcello J; Herndon JE; Bailey L; Peters KB; Friedman HS; Vredenburgh JJ
    Cancer; 2012 Mar; 118(5):1302-12. PubMed ID: 21792866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
    J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
    Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
    J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
    Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
    Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
    Addeo R; Caraglia M; De Santi MS; Montella L; Abbruzzese A; Parlato C; Vincenzi B; Carraturo M; Faiola V; Genovese M; Cennamo G; Del Prete S
    J Neurooncol; 2011 May; 102(3):417-24. PubMed ID: 20694830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
    Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
    Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
    J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
    Reardon DA; Desjardins A; Peters K; Gururangan S; Sampson J; Rich JN; McLendon R; Herndon JE; Marcello J; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
    J Neurooncol; 2011 Jun; 103(2):371-9. PubMed ID: 20853132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
    Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
    J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
    Omuro A; Chan TA; Abrey LE; Khasraw M; Reiner AS; Kaley TJ; Deangelis LM; Lassman AB; Nolan CP; Gavrilovic IT; Hormigo A; Salvant C; Heguy A; Kaufman A; Huse JT; Panageas KS; Hottinger AF; Mellinghoff I
    Neuro Oncol; 2013 Feb; 15(2):242-50. PubMed ID: 23243055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.